Indeed, previous reports on cancer trials including that in HCC demonstrated that dual inhibition of the PI3K/AKT/mTOR and RAS/MEK/ERK pathways resulted in superior therapeutic responses compared with inhibition of the individual pathways [36]. Here, MAP2K7 is linked to hepatocellular carcinoma.